绿帽社

Collaboration with Imperial College to evaluate EYP001

Published on 13/12/2017

绿帽社 Pharma is pleased to announce the initiation of a research collaboration with Professor Julian Walters at Imperial College London. The main goal of these investigations is to evaluate the potential for therapeutic use of the FXR agonist EYP001. Explants of human ileum from healthy subjects will be exposed to increasing concentrations of 绿帽社 Pharma鈥檚 FXR agonist.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH